{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T19:32:02Z","timestamp":1792006322184,"version":"4.4.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T00:00:00Z","timestamp":1748563200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T00:00:00Z","timestamp":1748563200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["186304"],"award-info":[{"award-number":["186304"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["JEAN21F0"],"award-info":[{"award-number":["JEAN21F0"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000156","name":"Fonds de Recherche du Qu\u00e9bec - Sant\u00e9","doi-asserted-by":"publisher","award":["295613"],"award-info":[{"award-number":["295613"]}],"id":[{"id":"10.13039\/501100000156","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000038","name":"Natural Sciences and Engineering Research Council of Canada","doi-asserted-by":"publisher","award":["RGPIN-06044"],"award-info":[{"award-number":["RGPIN-06044"]}],"id":[{"id":"10.13039\/501100000038","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Antimicrob Resist"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>The lack of novel antimicrobial compounds in the development pipeline cries for innovative approaches regarding their discovery. In this Perspective, we discuss how microbial interactions play a significant role in shifting a pathogen\u2019s response to antibacterial treatment and negatively impact patient outcomes. Furthermore, we argue that interspecies interactions are often overlooked in treatment selection and current drug screening approaches, and modeling disease-relevant polymicrobial communities could help in unraveling novel strategies to eradicate pathogens.<\/jats:p>","DOI":"10.1038\/s44259-025-00115-1","type":"journal-article","created":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T12:11:45Z","timestamp":1748607105000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Building microbial communities to improve antimicrobial strategies"],"prefix":"10.1038","volume":"3","author":[{"given":"Laurence","family":"Couture","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrice","family":"Jean-Pierre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Philippe","family":"C\u00f4t\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,30]]},"reference":[{"key":"115_CR1","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1128\/am.18.5.766-770.1969","volume":"18","author":"A Shahidi","year":"1969","unstructured":"Shahidi, A. & Ellner, P. D. Effect of mixed cultures on antibiotic susceptibility testing. Appl. Microbiol. 18, 766\u2013770 (1969).","journal-title":"Appl. Microbiol."},{"key":"115_CR2","first-page":"780","volume":"77","author":"BS Linn","year":"1975","unstructured":"Linn, B. S. & Szabo, S. The varying sensitivity to antibacterial agents of micro-organisms in pure vs. mixed cultures. Surgery 77, 780\u2013785 (1975).","journal-title":"Surgery"},{"key":"115_CR3","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1177\/1753425912439910","volume":"18","author":"A Nelson","year":"2012","unstructured":"Nelson, A., De Soyza, A., Perry, J. D., Sutcliffe, I. C. & Cummings, S. P. Polymicrobial challenges to Koch\u2019s postulates: Ecological lessons from the bacterial vaginosis and cystic fibrosis microbiomes. Innate Immun. 18, 774\u2013783 (2012).","journal-title":"Innate Immun."},{"key":"115_CR4","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1038\/s41579-022-00820-y","volume":"21","author":"EM Darby","year":"2023","unstructured":"Darby, E. M. et al. Molecular mechanisms of antibiotic resistance revisited. Nat. Rev. Microbiol. 21, 280\u2013295 (2023).","journal-title":"Nat. Rev. Microbiol."},{"key":"115_CR5","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/S0140-6736(05)70155-0","volume":"365","author":"KA Brogden","year":"2005","unstructured":"Brogden, K. A., Guthmiller, J. M. & Taylor, C. E. Human polymicrobial infections. Lancet 365, 253\u2013255 (2005).","journal-title":"Lancet"},{"key":"115_CR6","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1128\/CMR.00013-11","volume":"25","author":"BM Peters","year":"2012","unstructured":"Peters, B. M., Jabra-Rizk, M. A., O\u2019May, G. A., Costerton, J. W. & Shirtliff, M. E. Polymicrobial interactions: impact on pathogenesis and human disease. Clin. Microbiol. Rev. 25, 193\u2013213 (2012).","journal-title":"Clin. Microbiol. Rev."},{"key":"115_CR7","first-page":"e01456","volume":"0","author":"DW Rivett","year":"2024","unstructured":"Rivett, D. W., Hatfield, L. R., Gavillet, H., Hardman, M. & van der Gast, C. Bacterial interactions underpin worsening lung function in cystic fibrosis-associated infections. mBio 0, e01456\u201324 (2024).","journal-title":"mBio"},{"key":"115_CR8","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1038\/s41579-024-01035-z","volume":"22","author":"A Uberoi","year":"2024","unstructured":"Uberoi, A., McCready-Vangi, A. & Grice, E. A. The wound microbiota: microbial mechanisms of impaired wound healing and infection. Nat. Rev. Microbiol 22, 507\u2013521 (2024).","journal-title":"Nat. Rev. Microbiol"},{"key":"115_CR9","doi-asserted-by":"publisher","unstructured":"Orazi G. & O\u2019Toole G. A. \u201cIt Takes a Village\u201d: mechanisms underlying antimicrobial recalcitrance of polymicrobial biofilms. J. Bacteriol. https:\/\/doi.org\/10.1128\/jb.00530-19 (2019).","DOI":"10.1128\/jb.00530-19"},{"key":"115_CR10","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1007\/s10096-016-2621-0","volume":"35","author":"DH Limoli","year":"2016","unstructured":"Limoli, D. H. et al. Staphylococcus aureus and Pseudomonas aeruginosa co-infection is associated with cystic fibrosis-related diabetes and poor clinical outcomes. Eur. J. Clin. Microbiol. Infect. Dis. 35, 947\u2013953 (2016).","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"115_CR11","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2212340119","volume":"119","author":"CB Ibberson","year":"2022","unstructured":"Ibberson, C. B., Barraza, J. P., Holmes, A. L., Cao, P. & Whiteley, M. Precise spatial structure impacts antimicrobial susceptibility of S. aureus in polymicrobial wound infections. Proc. Natl Acad. Sci. USA 119, e2212340119 (2022).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"115_CR12","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.47365","volume":"8","author":"DH Limoli","year":"2019","unstructured":"Limoli, D. H. et al. Interspecies interactions induce exploratory motility in Pseudomonas aeruginosa. Elife 8, e47365 (2019).","journal-title":"Elife"},{"key":"115_CR13","doi-asserted-by":"crossref","unstructured":"Orazi, G. & O\u2019Toole, G. A. Pseudomonas aeruginosa alters Staphylococcus aureus sensitivity to vancomycin in a biofilm model of cystic fibrosis infection. mBio 8, e00873-17 (2017).","DOI":"10.1128\/mBio.00873-17"},{"key":"115_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/nmicrobiol.2017.79","volume":"2","author":"CB Ibberson","year":"2017","unstructured":"Ibberson, C. B. et al. Co-infecting microbes dramatically alter pathogen gene essentiality during polymicrobial infection. Nat. Microbiol. 2, 17079 (2017).","journal-title":"Nat. Microbiol."},{"key":"115_CR15","doi-asserted-by":"crossref","unstructured":"Millette, G. et al. Despite antagonism in vitro, Pseudomonas aeruginosa enhances Staphylococcus aureus colonization in a murine lung infection model. Front. Microbiol. 10, 2880 (2019).","DOI":"10.3389\/fmicb.2019.02880"},{"key":"115_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41385-018-0053-0","volume":"12","author":"MT Sorbara","year":"2019","unstructured":"Sorbara, M. T. & Pamer, E. G. Interbacterial mechanisms of colonization resistance and the strategies pathogens use to overcome them. Mucosal Immunol. 12, 1\u20139 (2019).","journal-title":"Mucosal Immunol."},{"key":"115_CR17","unstructured":"Rogers A. W. L., Tsolis R. M. & B\u00e4umler A. J. Salmonella versus the microbiome. Microbiol. Mol. Biol. Rev. 85:e00027-19."},{"key":"115_CR18","doi-asserted-by":"crossref","unstructured":"Blais L., Couture L., Laforest-Lapointe I. & C\u00f4t\u00e9 J. P. Lactobacilli decrease the susceptibility of Salmonella typhimurium to azithromycin. Microbiol. Spectrum. e03497-23 (2024).","DOI":"10.1128\/spectrum.03497-23"},{"key":"115_CR19","doi-asserted-by":"publisher","DOI":"10.1128\/mbio.00235-22","volume":"13","author":"M Zhang","year":"2022","unstructured":"Zhang, M., Whiteley, M. & Lewin, G. R. Polymicrobial interactions of oral microbiota: a historical review and current perspective. mBio 13, e0023522 (2022).","journal-title":"mBio"},{"key":"115_CR20","doi-asserted-by":"crossref","unstructured":"Falsetta, M. L. et al. Symbiotic relationship between Streptococcus mutans and Candida albicans synergizes virulence of plaque biofilms in vivo. Infect. Immun. 82, 1968\u20131981 (2014).","DOI":"10.1128\/IAI.00087-14"},{"key":"115_CR21","doi-asserted-by":"publisher","first-page":"1812","DOI":"10.1093\/cid\/ciz364","volume":"69","author":"VJ Waters","year":"2019","unstructured":"Waters, V. J. et al. Reconciling antimicrobial susceptibility testing and clinical response in antimicrobial treatment of chronic cystic fibrosis lung infections. Clin. Infect. Dis. 69, 1812\u20131816 (2019).","journal-title":"Clin. Infect. Dis."},{"key":"115_CR22","doi-asserted-by":"publisher","first-page":"S46","DOI":"10.1093\/jpids\/piac040","volume":"11","author":"JJ LiPuma","year":"2022","unstructured":"LiPuma, J. J. The sense and nonsense of antimicrobial susceptibility testing in cystic fibrosis. J. Pediatr. Infect. Dis. Soc. 11, S46\u2013S52 (2022).","journal-title":"J. Pediatr. Infect. Dis. Soc."},{"key":"115_CR23","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.00006-21","volume":"12","author":"F Jean-Pierre","year":"2021","unstructured":"Jean-Pierre, F., Vyas, A., Hampton, T. H., Henson, M. A. & O\u2019Toole, G. A. One versus many: polymicrobial communities and the cystic fibrosis airway. mBio 12, e00006-21 (2021).","journal-title":"mBio"},{"key":"115_CR24","doi-asserted-by":"publisher","DOI":"10.1128\/cmr.00024-23","volume":"36","author":"T Coenye","year":"2023","unstructured":"Coenye, T. Biofilm antimicrobial susceptibility testing: where are we and where could we be going? Clin. Microbiol Rev. 36, e0002423 (2023).","journal-title":"Clin. Microbiol Rev."},{"key":"115_CR25","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1016\/j.jcf.2023.02.001","volume":"22","author":"AV Faino","year":"2023","unstructured":"Faino, A. V. et al. Polymicrobial infections and antibiotic treatment patterns for cystic fibrosis pulmonary exacerbations. J. Cyst. Fibros. 22, 630\u2013635 (2023).","journal-title":"J. Cyst. Fibros."},{"key":"115_CR26","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.jcf.2022.08.001","volume":"22","author":"JD Cogen","year":"2023","unstructured":"Cogen, J. D. et al. Antibiotics and outcomes of CF pulmonary exacerbations in children infected with MRSA and Pseudomonas aeruginosa. J. Cyst. Fibros. 22, 313\u2013319 (2023).","journal-title":"J. Cyst. Fibros."},{"key":"115_CR27","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1038\/nrmicro1955","volume":"6","author":"SA Brown","year":"2008","unstructured":"Brown, S. A., Palmer, K. L. & Whiteley, M. Revisiting the host as a growth medium. Nat. Rev. Microbiol. 6, 657\u2013666 (2008).","journal-title":"Nat. Rev. Microbiol."},{"key":"115_CR28","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1046\/j.1472-765X.1997.00378.x","volume":"24","author":"T Brooks","year":"1997","unstructured":"Brooks, T. & Keevil, C. w. A simple artificial urine for the growth of urinary pathogens. Lett. Appl. Microbiol. 24, 203\u2013206 (1997).","journal-title":"Lett. Appl. Microbiol."},{"key":"115_CR29","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2022.948151","volume":"12","author":"J Stamm","year":"2022","unstructured":"Stamm, J. et al. Development of an artificial synovial fluid useful for studying Staphylococcus epidermidis joint infections. Front. Cell Infect. Microbiol 12, 948151 (2022).","journal-title":"Front. Cell Infect. Microbiol"},{"key":"115_CR30","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.01980-24","volume":"13","author":"A De Bleeckere","year":"2024","unstructured":"De Bleeckere, A. et al. A novel synthetic synovial fluid model for investigating biofilm formation and antibiotic susceptibility in prosthetic joint infections. Microbiol. Spectr. 13, e01980-24 (2024).","journal-title":"Microbiol. Spectr."},{"key":"115_CR31","doi-asserted-by":"publisher","first-page":"4110","DOI":"10.1073\/pnas.1419677112","volume":"112","author":"KH Turner","year":"2015","unstructured":"Turner, K. H., Wessel, A. K., Palmer, G. C., Murray, J. L. & Whiteley, M. Essential genome of Pseudomonas aeruginosa in cystic fibrosis sputum. Proc. Natl Acad. Sci. USA 112, 4110\u20134115 (2015).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"115_CR32","doi-asserted-by":"publisher","unstructured":"Orazi, G., Ruoff, K. L., O\u2019Toole, G. A. Pseudomonas aeruginosa increases the sensitivity of biofilm-grown Staphylococcus aureus to membrane-targeting antiseptics and antibiotics. mBio. https:\/\/doi.org\/10.1128\/mbio.01501-19 (2019).","DOI":"10.1128\/mbio.01501-19"},{"key":"115_CR33","doi-asserted-by":"publisher","first-page":"e00159","DOI":"10.1128\/JB.00159-20","volume":"202","author":"G Orazi","year":"2020","unstructured":"Orazi, G., Jean-Pierre, F. & O\u2019Toole, G. A. Pseudomonas aeruginosa PA14 enhances the efficacy of norfloxacin against Staphylococcus aureus Newman biofilms. J. Bacteriol. 202, e00159\u201320 (2020).","journal-title":"J. Bacteriol."},{"key":"115_CR34","doi-asserted-by":"publisher","DOI":"10.1128\/jb.00073-24","volume":"206","author":"GA O\u2019Toole","year":"2024","unstructured":"O\u2019Toole, G. A. We have a community problem. J. Bacteriol. 206, e00073-24 (2024).","journal-title":"J. Bacteriol."},{"key":"115_CR35","doi-asserted-by":"publisher","first-page":"2765","DOI":"10.1038\/s41564-024-01827-2","volume":"9","author":"EC Mehlferber","year":"2024","unstructured":"Mehlferber, E. C. et al. A cross-systems primer for synthetic microbial communities. Nat. Microbiol. 9, 2765\u20132773 (2024).","journal-title":"Nat. Microbiol."},{"key":"115_CR36","doi-asserted-by":"publisher","DOI":"10.1093\/femsre\/fuad012","volume":"47","author":"PT van Leeuwen","year":"2023","unstructured":"van Leeuwen, P. T., Brul, S., Zhang, J. & Wortel, M. T. Synthetic microbial communities (SynComs) of the human gut: design, assembly, and applications. FEMS Microbiol. Rev. 47, fuad012 (2023).","journal-title":"FEMS Microbiol. Rev."},{"key":"115_CR37","doi-asserted-by":"publisher","DOI":"10.1038\/nmicrobiol.2016.215","volume":"2","author":"S Brugiroux","year":"2016","unstructured":"Brugiroux, S. et al. Genome-guided design of a defined mouse microbiota that confers colonization resistance against Salmonella enterica serovar Typhimurium. Nat. Microbiol 2, 16215 (2016).","journal-title":"Nat. Microbiol"},{"key":"115_CR38","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.81604","volume":"12","author":"F Jean-Pierre","year":"2023","unstructured":"Jean-Pierre, F. et al. Community composition shapes microbial-specific phenotypes in a cystic fibrosis polymicrobial model system. Elife 12, e81604 (2023).","journal-title":"Elife"},{"key":"115_CR39","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1038\/nature17042","volume":"529","author":"ED Brown","year":"2016","unstructured":"Brown, E. D. & Wright, G. D. Antibacterial drug discovery in the resistance era. Nature 529, 336\u2013343 (2016).","journal-title":"Nature"},{"key":"115_CR40","doi-asserted-by":"publisher","first-page":"e88","DOI":"10.1016\/S1473-3099(21)00122-5","volume":"22","author":"T Bjarnsholt","year":"2022","unstructured":"Bjarnsholt, T. et al. The importance of understanding the infectious microenvironment. Lancet Infect. Dis. 22, e88\u2013e92 (2022).","journal-title":"Lancet Infect. Dis."},{"key":"115_CR41","doi-asserted-by":"publisher","first-page":"a030239","DOI":"10.1101\/cshperspect.a030239","volume":"6","author":"LL Silver","year":"2016","unstructured":"Silver, L. L. Appropriate targets for antibacterial drugs. Cold Spring Harb. Perspect. Med. 6, a030239 (2016).","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"115_CR42","doi-asserted-by":"crossref","unstructured":"Skurnik, D. et al. A comprehensive analysis of in vitro and in vivo genetic fitness of Pseudomonas aeruginosa using high-throughput sequencing of transposon libraries. PLoS Pathog. 9, e1003582 (2013).","DOI":"10.1371\/journal.ppat.1003582"},{"key":"115_CR43","doi-asserted-by":"publisher","unstructured":"Umland, T. C. et al. In vivo-validated essential genes identified in Acinetobacter baumannii by using human ascites overlap poorly with essential genes detected on laboratory media. mBio. https:\/\/doi.org\/10.1128\/mbio.00113-12 (2012).","DOI":"10.1128\/mbio.00113-12"},{"key":"115_CR44","doi-asserted-by":"publisher","DOI":"10.1128\/AEM.00691-20","volume":"86","author":"AE Shea","year":"2020","unstructured":"Shea, A. E. et al. Escherichia coli CFT073 fitness factors during urinary tract infection: identification using an ordered transposon library. Appl. Environ. Microbiol. 86, e00691-20 (2020).","journal-title":"Appl. Environ. Microbiol."},{"key":"115_CR45","doi-asserted-by":"crossref","unstructured":"Cornforth, D. M., Diggle, F. L., Melvin, J. A., Bomberger, J. M. & Whiteley, M. Quantitative framework for model evaluation in microbiology research using Pseudomonas aeruginosa and cystic fibrosis infection as a test case. mBio 11, e03042-19 (2020).","DOI":"10.1128\/mBio.03042-19"},{"key":"115_CR46","doi-asserted-by":"crossref","unstructured":"Li, L. et al. An in vitro model maintaining taxon-specific functional activities of the gut microbiome. Nat. Commun. 10, 4146 (2019).","DOI":"10.1038\/s41467-019-12087-8"},{"key":"115_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2020.107927","volume":"32","author":"BS Weber","year":"2020","unstructured":"Weber, B. S. et al. Genetic and chemical screening in human blood serum reveals unique antibacterial targets and compounds against Klebsiella pneumoniae. Cell Rep. 32, 107927 (2020).","journal-title":"Cell Rep."},{"key":"115_CR48","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.00352-23","volume":"11","author":"G Di Bonaventura","year":"2023","unstructured":"Di Bonaventura, G. et al. Repurposing high-throughput screening identifies unconventional drugs with antibacterial and antibiofilm activities against Pseudomonas aeruginosa under experimental conditions relevant to cystic fibrosis. Microbiol. Spectr. 11, e00352-23 (2023).","journal-title":"Microbiol. Spectr."},{"key":"115_CR49","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2221542120","volume":"120","author":"GR Lewin","year":"2023","unstructured":"Lewin, G. R. et al. Application of a quantitative framework to improve the accuracy of a bacterial infection model. Proc. Natl Acad. Sci. USA 120, e2221542120 (2023).","journal-title":"Proc. Natl Acad. Sci. USA"}],"container-title":["npj Antimicrobials and Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s44259-025-00115-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s44259-025-00115-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s44259-025-00115-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T12:11:47Z","timestamp":1748607107000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s44259-025-00115-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,30]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["115"],"URL":"https:\/\/doi.org\/10.1038\/s44259-025-00115-1","relation":{},"ISSN":["2731-8745"],"issn-type":[{"value":"2731-8745","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,30]]},"assertion":[{"value":"26 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"46"}}